The 2008 UK national chronic obstructive pulmonary disease (COPD) audit examined the use of supported discharge programmes (SDPs) in clinical practice against British Thoracic Society guidelines. 98% of acute UK trusts participated. SDPs were available in 142 of 239 (59%) units. 1630 of 8971 (18%) patients with COPD were treated within SDPs. Median (IQR) stay in hospital for patients within SDPs and those not accepted for SDPs was 3 (1e6) days and 6 (3e11) days (p<0.001), and mortality within 90 days of admission was 4.3% and 6.7%, respectively. SDPs within the UK are safe and effective and reduce length of hospital stay without adverse effects on mortality.
INTRODUCTION
Over recent years alternative models to hospitalisation for managing exacerbations of chronic obstructive pulmonary disease (COPD) have been developed in the form of 'supported discharge programmes' (SDPs), which aim to avoid hospitalisation or to reduce length of hospital stay (LOS) without affecting the safety of patient care. 1e4 In 2008, the Royal College of Physicians, the British Thoracic Society (BTS) and the British Lung Foundation undertook a national audit of the acute care of patients with COPD. This report reviews the data related to SDPs against audit standards described in BTS guidelines 2007. 2 
METHODS
All UK hospital trusts were eligible and each participating unit, defined as 'a hospital admitting acute unselected emergency admissions', completed a retrospective case note audit of up to 60 consecutive patients with admission due to COPD exacerbation identified prospectively between March and May 2008. 5 The audit collected SDP data about resources and organisation of care and clinical outcomes. Also nine SDP quality indicators (table 1) were derived from BTS guidelines and units indicated whether each indicator was met in full (score 2), partially met (score 1) or not met at all (score 0). These scores were summed and scaled from 0 to 100 to give a SDP quality score for each unit. Similar quality scores were derived for noninvasive ventilation, pulmonary rehabilitation and long-term oxygen therapy. Data were entered by units onto a bespoke web tool and collated centrally at the Royal College of Physicians. Ethics approval was given by University College Hospital/ University College London Multicentre Research Ethics Committee (MREC). Data were analysed using SPSS V.15. Numerical data were compared using the ManneWhitney U test, and categorical data using Fisher 's exact or c 2 test.
RESULTS
Overall 239 'units' from 180 of 184 acute NHS trusts across the UK contributed to the 2008 national COPD audit. A total of 142 (59%) units reported access to SDPs. Of 9716 audit patients, 745 (7.7%) died in hospital and of 8971 discharged patients (mean age (SD) 72 (10) years; forced expiratory volume in 1 s 41% (19%) predicted), 1630 (18%) were treated within SDPs. For units treating one or more audit patients within SDPs, the median LOS (IQR) was 3 (1e6) days for 1630 patients treated within SDPs, and 6 (3e11) days for 3376 patients not accepted for SDPs (p<0.001). The mortality rate at 90 days after admission was 4.3% (69 of 1591) for patients treated within SDPs and 6.7% (212 of 3172) for patients not accepted for SDPs (p¼0.001), with little difference in readmission rates at 34% and 35%, respectively (p¼0.54). Units providing SDPs reported better organisation and quality than other units, in measures such as having local COPD guidelines (75% vs 56%, p¼0.003), discharge guidelines (54% vs 32%, p¼0.001), non-invasive ventilation quality score (lowest quartile 17% vs 33%, p¼0.005), access for all patients with COPD to respiratory nursing (89% vs 67%, p<0.001) and any access to formal pulmonary rehabilitation (94% vs 84%, p¼0.02). Units offering SDPs had lower inpatient and 90-day mortality, and lower median LOS than units without SDPs, with no significant difference in readmission rates (table 2) .
The median (IQR) of SDP quality scores for units running an SDP was 83 (72e94). Professionals most directly involved with SDPs were respiratory nurses (96%, 136 of 142), respiratory consultants (77%, 109 of 142) and physiotherapists (59%, 84). Of 142 units providing SDPs, 16% (23) provided admission prevention, 35% (50) rapid discharge within 48 h of admission, 20% (28) rapid discharge over 48 h from admission, and 18% (25) admission prevention and rapid discharge within and over 48 h. There was little difference between schemes in patient mortality, readmission or time spent within schemes. Units offering all three types of schemes accepted more patients for SDPs (median 39% vs 25%, p¼0.03) and had lower median LOS (median (IQR) 4 (3e5) vs 6 (5e7) days, p<0.001). Most units provided 5-day (65%, 92 of 142) or 7-day services (25%, 35 of 142). There was little difference in patient mortality and readmission rates but 7-day services had lower LOS (median (IQR) 5 (4e6) days vs 6 (5e8) days, p¼0.004) and more whole time equivalent of staff involved (median (IQR) 8 (5e13) vs 6 (4e8), p¼0.009).
At least 15% (225 of 1630) of patients accepted to SDPs were outside of BTS guideline criteria, as evidenced by the presence of Locally adapted written protocols for the management of patients with COPD requiring NIV, including weaning from NIV, are available in all relevant clinical areas for all relevant staff There is continuous data collection along with prospective and annual audits of the service to monitor its effectiveness A selection of nasal and full face masks, types and nasal pillows are available; all areas offering NIV provide written information for patients about the indications for and patient experience of NIV There is a written policy for providing patient information about NIV to patients with severe while in a stable state, for example, in an outpatient setting or upon discharge from hospital There is an annual audit of the use of NIV, including all clinical areas; this audit covers patients offered NIV to examine its appropriate use and those that might have benefited from NIV but who were not provided with this therapy COPD, chronic obstructive pulmonary disease; HDU, high dependency unit; ICU, intensive care unit; NIV, non-invasive ventilation; SDP, supported discharge programme. 
DISCUSSION
This report provides information on the largest number of patients treated through SDPs from a single study. 1e4 The findings from this observational audit suggest that SDPs for treating acute exacerbations of COPD are safe, reduce LOS and address queries raised by BTS guidelines. 2 In the UK in 2008, 59% of units provided SDPs, a relative increase of 31% since the 2003 UK COPD audit. 4 Overall 18% (33% in units with access to SDPs) of patients with COPD with acute exacerbations were accepted onto SDPs, supporting estimates from current BTS guidelines.
2 For units treating one or more audit patients within SDPs, patients treated through SDPs had good outcomes with lower mortality at 90 days after admission than patients not participating in SDPs. Units not offering SDPs had higher inhospital and 90-day mortality, higher median LOS and more patients staying in hospital for at least 7 days (table 2). A proportion of patients treated within SDPs had abnormal chest radiographs, several comorbidities or lived alone (table 2), suggesting that with careful selection some patients can be managed within SDPs outside of the criteria described by current BTS guidelines. 2 The most common type of SDP was rapid discharge within 48 h of admission. Units providing a combination of schemes accepted more patients for SDPs and had lower overall median LOS. Similarly, units with 7-day SDPs had shorter median LOS. Our data suggest that the optimal type of service is one that combines prevention and rapid discharge within and over 48 h with 7-day service provision. This requires higher staffing levels and would be of particular relevance to larger units. For smaller units a 5-day service using early discharge within 48 h of admission may be more appropriate. These observations support the recommendations from the current BTS guidelines. 2 In conclusion, this study reported increased access and provision of SDPs in the UK and considers SDPs as safe, accepted and potentially cost effective through reduction of LOS. In the UK, almost a fifth of patients with COPD with acute exacerbations that required hospitalisation were treated within SDPs and this could be raised to at least one-third if currently applied criteria were extended to the whole of the UK. Our data revealed that more extensive SDP programmes treated more patients and had lower LOS which commissioners may find appealing. More importantly, as there were a number of positive organisational features that correlated with having SDPs, such as local guidelines, respiratory specialist nursing and access to pulmonary rehabilitation, commissioners should engage with the units who do not currently have SDPs in discussions to institute this safe and increasingly well established service. 
